

A pioneer in sequencing, genotyping and bioinformatics since 2001, GenoScreen offers innovative genomics services and solutions to meet the needs of healthcare professionals, academic and industrial research teams.

We are covering major fields :

Health



Agro-industry



Environment



Cosmetics



GNSDMTB042022

DEEPLEX[®]MYC-TB

TUBERCULOSIS MULTI-DRUG SUSCEPTIBILITY TEST



- ✓ **Comprehensive** : 15 anti-TB drugs screened
- ✓ **Sensitive** : Detection of heteroresistance down to 3%
- ✓ **Fast** : Culture-free / results in 24-48h
- ✓ **Innovative** : Based on deep sequencing / secure cloud-based sequencing data processing
- ✓ **Accessible** : Automated analysis, visualization and interpretation with the Deplex[®] WebApp
- ✓ **Evolutive** : Databases continuously updated
- ✓ **Beyond TB drug resistance** : Identification of >100 mycobacterial species and genotyping of TB strains

THE POWER OF DNA FOR ACCURATE DIAGNOSTICS



ISO 9001
ISO 13485
BUREAU VERITAS
Certification



GenoScreen
1 Rue du Professeur Calmette
59000 Lille, France
contact@genoscreen.fr
+33(0) 362 263 777

GLOBAL IMPACT OF TUBERCULOSIS (TB)

In 2020, an estimated 10 million people fell ill with TB

1.5 million people died from TB

Second leading infectious killer after COVID-19

Death from TB could increase by 20% due to COVID-19 by 2027

In 2019, WHO estimated 500 000 new cases of MDR (multi drug resistant)-TB

2/3 of people with drug-resistant TB are not detected

TUBERCULOSIS DRUG RESISTANCE ASSAY CULTURE-FREE, BASED ON DEEP SEQUENCING

DEEPLEX® MYC-TB

is a culture-free molecular test for:

- Prediction of TB resistance to 15 antibiotics
- Mycobacterial species identification
- TB strain genotyping & spoligotyping

THE KIT :

Includes access to the Deeplex® web application for **rapid analysis** of sequencing data and **intuitive** and **interactive** visualization and interpretation of the **results**.



"We developed this product to provide a robust and rapid diagnostic solution for tuberculosis and its drug resistance to better assist clinicians in the management of tuberculosis patients around the world."



André Tordeux, CEO

GenoScreen
Innovative Genomics

References

World Health Organisation 2021. Tuberculosis Key Fact 2021
TAG, Pipeline report 2021 : Tuberculosis Diagnostics
<https://www.genoscreen.fr/fr/genoscreen-services/produits/deeplex>

